Compare PepsiCo, Inc. (PEP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs TransMedics Group Inc — how do they compare? PepsiCo, Inc. trades at $126.13 (market cap $174.89B), while TransMedics Group Inc trades at $78.32 (market cap $2.74B). The key difference: PepsiCo, Inc. is far larger — about 63.8× TransMedics Group Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and TransMedics Group Inc for 24 Days on average.
| PEP | TMDX | |
|---|---|---|
Market Cap | $174.89B | $2.74B |
Volume | 23,968,864 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $150.42 |
52-Week Low | $123.64 | $61.99 |
Typical Hold Time | 107 Days | 24 Days |
Enterprise Value | $215.61B | $3.13B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $125.80, up 1.74% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. Revenue grew to $93.93B in 2025, with a net margin of 10.78% and robust cash flow. Analyst consensus is a Buy with a $146.77 price target, though recent news highlights pricing pressures in snacks.
The outlook is mixed: strong profitability and institutional support offer upside, but bearish technicals and consumer pushback on high prices pose near-term risks. Execution on North American turnaround and margin expansion will be critical for sustained growth amid competitive and macroeconomic challenges.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
